Tuberous Sclerosis Complex
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
Vigabatrin may be an effective option for patients with seizures due to tuberous sclerosis who do not respond to other anti-seizure treatments.
Adjunctive everolimus treatment has been found to significantly reduce frequency of treatment-resistant seizures in TSC.
The EXIST-3 trial is the first phase 3 study to evaluate the use of EVE for the adjunctive treatment of seizures in TSC.
The drug, which is indicated to treat certain types of cancer, is effective at reducing seizures in TSC when used as adjunctive therapy.
Neurology Advisor Articles
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Women With Epilepsy More Likely to Have Major Depressive Disorder
- Some Common Allergies Linked to Odds of Autism in Children
- CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
- Long-Term Type 1 Diabetes Associated With Cognitive Decline
- White Matter Hyperintensities in RCVS Vary Over Time
- Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease
- Levetiracetam Effective as Episodic Migraine Prophylactic